Clinical Trials Logo

Clinical Trial Summary

Pneumocystis jirovecii is a fungus that can colonize the airways of some patients and be responsible for a disease called pneumocystosis in other patients and mainly in immunocompromised patients. Pneumocystosis was mainly linked to HIV in the 1990s, but with the advent of new immunosuppressive molecules used in cancers or autoimmune diseases and with the increase in the number of transplants, the epidemiology has changed in recent years. Studies on P. jirovecii-related mortality are only based on patients with pneumocystosis. As a result, patients who are simply colonized or patients who are sick but not treated are not taken into account in these studies. The investigators therefore wish to study the overall mortality at six weeks and at three months in all patients with a positive sample for P. jirovecii


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06173453
Study type Observational
Source University Hospital, Strasbourg, France
Contact François DANION, MD
Phone 33 3 69 55 15 88
Email Francois.danion@chru-strasbourg.fr
Status Recruiting
Phase
Start date January 1, 2023
Completion date October 10, 2025

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04851015 - Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia Phase 3
Completed NCT05707156 - Prospective Observational Study on the Incidence of Opportunistic Fungal Infections
Completed NCT05458752 - Pneumocystis Jirovecii Pneumonia in Non-HIV-infected Immunocompromised Patients